Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sintilimab plus pemetrexed and platinum for first-line unresectable malignant pleural mesothelioma
ChiCTR2400086243Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, pemetrexed, cisplatin and carboplatin in pleural mesothelioma, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
sintilimabpemetrexedcisplatincarboplatin
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on ChiCTR2400086243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086243.